Table 1.

Prevalence of antibodies to HERV-K10 Gag and Pol peptides in different populations

	VBD		LGLL		HTLVt		HTLVm		HTLVn		MS
Peptides	#tested	#pos (%)	#tested	#pos (%)	#tested	#pos (%)	#tested	#pos (%)	#tested	#pos (%)	#tested	#pos (%)
HERV-K10 Gag*	100	7(7)	53	0(0)	74	18(24)	16	14(88)	58	4(7)	83	9(11)
HERV-K10 Pol+	100	0(0)	53	3(6)	74	21(28)	16	15(94)	58	6(10)	83	13(16)

*HERV-K10 Gag VBD vs. LGLL, p = 0.047; VBD vs. all HTLV+, p = 0.001; VBD vs. HTLV + myelopathy, p = < 0.001: VBD vs. HTLV + non-myelopathy, p = 0.626; VBD vs. multiple sclerosis, p = 0.256; HTLV + myelopathy vs. HTLV + non-myelopathy, p = <0.001; HTLV + myelopathy vs. MS p = < 0.001.

⁺HERV-K10 Pol VBD vs. LGLL, p = 0.040; VBD vs. all HTLV+, p = 0.001; VBD vs. HTLV + myelopathy, p = < 0.001: VBD vs. HTLV + non-myelopathy, p = 0.002; VBD vs. multiple sclerosis, p = < 0.001; HTLV + myelopathy vs. HTLV + non-myelopathy, p = <0.001; HTLV + myelopathy vs. MS, p = < 0.001.